Showing 3551-3560 of 5646 results for "".
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Regeneron to Present 27 New Eylea HD Injection 8 mg Abstracts and Presentations at ARVOhttps://modernod.com/news/regeneron-to-present-27-new-eylea-hd-injection-8-mg-abstracts-and-presentations-at-arvo/2482766/Regeneron announced the upcoming presentation of 27 abstracts, including eight oral presentations on Eylea HD (aflibercept) Injection 8 mg in wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR). Among the new results and analyses are initia
- Alcon Launches UNITY VCS and UNITY CS for for Vitreoretinal and Cataract Surgeryhttps://modernod.com/news/alcon-launches-unity-vcs-and-unity-cs-for-for-vitreoretinal-and-cataract-surgery/2482763/Alcon announced the launch of the UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS). The platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). It is designed to deliver superior efficiency for vit
- University of Cincinnati Study Finds Fear of Vision Loss is a Barrier to Cataract Surgeryhttps://modernod.com/news/university-of-cincinnati-study-finds-fear-of-vision-loss-is-a-barrier-to-cataract-surgery/2482761/Fear of vision loss, particularly among patients who have a visually significant cataract in only one eye, may deter some from undergoing cataract surgery, according to a new study from the Department of Ophthalmology at the University of Cincinnati (UC). The study,
- iStar Medical Announces Positive 5-year Results of MINIject® in Glaucoma Patientshttps://modernod.com/news/istar-medical-announces-positive-5-year-results-of-miniject-in-glaucoma-patients/2482760/iStar Medical has announced positive 5-year results from the STAR-GLOBAL trial for their MINIject®device in patients with open-angle glaucoma. STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of MINIject® up to five years after im
- Focus Vitamins Launches New Daily Eye Health Supplement: Focus Luteinhttps://modernod.com/news/focus-vitamins-launches-new-daily-eye-health-supplement-focus-lutein/2482758/Focus Vitamins, a physician-founded nutraceutical company under Covalent Medical, has announced the launch of 'Focus Lutein,' a daily eye health supplement designed to support long-term vision and defend against age-related changes.
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- Allotex Accelerates into Commercial Phase and Appoints Michael Mrochen as New CEOhttps://modernod.com/news/allotex-accelerates-into-commercial-phase-and-appoints-michael-mrochen-as-new-ceo/2482755/Allotex, which has developed the first natural, human collagen-based eye implant designed to help people over 40 restore their near vision, announced progress in its commercial rollout across global markets. Following market clearance in Europe, Canada, South Africa, Türkiye, and A
- First Atropine Eye Drop to Slow Myopia Progression in Children Approved in Indiahttps://modernod.com/news/first-atropine-eye-drop-to-slow-myopia-progression-in-children-approved-in-india/2482750/Entod Pharmaceuticals announced it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the first 0.05% atropine eye drops (Myatro XL) developed to slow the progression of myopia in children age 6 to 12. This milestone foll
- MicroSurgical Technology (MST) to Discuss Advances in Vitrectomy Technology at ASCRShttps://modernod.com/news/microsurgical-technology-mst-to-discuss-advances-in-vitrectomy-technology-at-ascrs/2482749/MicroSurgical Technology (MST) announced it will share research during two presentations on the Vista 1-Step novel vitrectomy probe at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28. The